USSTOCK.TODAY
Regular Market
Log in Sign up
Company overview

What Does Careling Brands (CABR) Do? — Stock Outlook, Earnings, Market Cap, Peers, and Headquarters

Updated September 3, 2026 · First published May 14, 2026

Careling Brands (CABR) is a New York-based company developing OTC therapeutics for skin conditions, distinguished by a diverse dermatology pipeline and pipeline of new products.

Briefs · earnings · signals, first Subscribe

🏢 What kind of company is Careling Brands?

What Does Careling Brands live price & charts, on one page Check anytime curiosity strikes while reading

Careling Brands is a New York-based company that develops OTC consumer products for skin conditions and health-related needs. It develops a wide range of dermatology solutions, from treatments for psoriasis, vitiligo, and eczema to hair care and women's wellness products.

It develops a diverse portfolio of OTC and cosmetic products, including Photocil (psoriasis and vitiligo), Hair Enzyme Booster (hair loss), CB-101 (eczema), jellyfish-sting-prevention sunscreen, and women's wellness products. The company is pursuing expansion of its product portfolio based on dermatology innovation and patient demand.

💰 How does Careling Brands make money?

Business SegmentRevenue MixDescription
Skin-condition TherapeuticsIn developmentClinical and marketing preparation
Healthcare ProductsEarly stageWomen's wellness, etc.

Careling Brands is at an extremely early revenue stage on the order of - and has not yet generated revenue at commercial scale. The company is focused on the product development and regulatory approval stages, and future OTC product approvals and market entry are key to revenue generation.

📐 Careling Brands Market Cap and Company Scale

Market cap and employee count are not currently disclosed.

The market cap reflects an early-stage development company that has yet to achieve profitability. Observers have raised questions about the company's viability, and securing funding and successfully commercializing products are critical to its survival.

📈 Careling Brands Outlook and Stock Price Trends

1-Year Price Performance
Analyst Consensus
No analyst coverage
Small-cap or newly listed stocks may not have valuation data collected.
52-Week Price Range
$1
Low $1 High $6
vs. low +76.01% vs. high -79.17%

In the short term, regulatory approval and the initial launch of key products such as Photocil are the main variables. Over the medium to long term, growth in the skin-condition OTC market and the expansion of a diversified product portfolio represent the growth path. However, funding shortfalls, limited experience, and slower market entry compared with competitors pose existential threats.

  • Regulatory approval and market entry of skin-condition OTC products
  • Expansion of the healthcare product portfolio
  • Acceleration of R&D through additional capital raises

⚔️ Careling Brands Core Competitive Strengths and Risks

An innovative skin-condition product portfolio is a strength, but the lack of early revenue, funding pressure, and survival uncertainty are serious risks.

💪 Core Competitive Strengths

Product Diversification
It develops a diverse range of dermatology products spanning psoriasis, eczema, hair loss, and wellness.
Unmet Demand
The skin-condition OTC market has large patient demand and limited existing treatments.
Lower Barriers to Entry
OTC products face lower regulatory barriers than prescription drugs.

⚠️ Core Risks

Early-Stage Revenue
No commercial-scale revenue yet, leaving the company entirely dependent on cash burn.
Funding Shortfall
Observers have raised serious questions about the company's viability.
Competitive Entry
Large pharmaceutical companies can also enter the same market, making the establishment of a market advantage uncertain.

🔄 Careling Brands Competitors and Related (Beneficiary) Stocks

In the skin-condition OTC market, AXIL, ELAB, and FTLF, among others, are active as competitors, while WALD and UPXI also operate in the wellness market.

Competitors
TickerCompanyPriceChangeMarket CapP/EPBRROEDividend Yield
SNGXSNGXSoligenix Inc$0.38-0.8%$8.3M-1.2-241.65%-
Related stocks (beneficiaries)
TickerCompanyPriceChangeMarket CapP/EPBRROEDividend Yield
KVUEKenvue Inc$18.74-1.1%$36.0B21.73.415.58%4.51%
PGProcter & Gamble Co$146.44-0.3%$340.4B22.16.430.25%2.99%
View Related Stocks at a Glance on the Real-Time Dashboard Check screeners, heatmaps, and real-time quotes all on one screen

✅ Careling Brands Investor Checklist

Careling Brands is an early-stage company focused on innovative development of skin-condition OTC products. It is built on a diversified product portfolio and unmet medical demand.

ChecklistWhat to ConfirmCurrent Status
📋 Regulatory ApprovalProgress on FDA approval of key products such as PhotocilPending
💰 Funding SituationSuccess of additional capital raisesCrisis
📈 CommercializationInitial product sales and revenue generationNot started

The company's survival itself is under threat. Funding shortfalls, lack of revenue, and observers' concerns about viability are serious. If regulatory approval and initial sales launches are not achieved, the company is likely to cease to exist.

An innovative skin-condition product portfolio is an intriguing point for investors, but the company's survival and ability to secure funding are absolute prerequisites. Only investors willing to accept extreme high risk as an early-stage company should consider it. Regulatory approval news and progress on capital raises need to be monitored on an ongoing basis.

You've read this far. Time to see the numbers See What Does Careling Brands live charts, financials & analyst views
Briefs · earnings · signals, first Subscribe
US STOCK TODAY Editorial Team
Every figure is calculated directly from filings and market data. How we work
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →